Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Lingor

Showing results (141-150 of 173) with videos related to

Pageof 18
Sort By:
Annals of Clinical and Translational Neurology|April 1, 2021
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatmentMaren Freigang, Claudia D Wurster, Tim Hagenacker, et al.
Neurobiology of Disease|August 10, 2018
Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi functionIsabel Paiva, Gaurav Jain, Diana F Lázaro, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 20, 2026
Minimum important slowing of disease progression as determined by the ALS functional rating scale - a survey of patient expectations toward disease-modifying drugs in ALSThomas Meyer, André Maier, Torsten Grehl, et al.
JAMA Neurology|January 10, 2022
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral SclerosisSimon Witzel, André Maier, Robert Steinbach, et al.
Nature Communications|January 11, 2022
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescentsNina Koerber, Alina Priller, Sarah Yazici, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 9, 2025
"The DESCRIBE-ALS-FTD study: a prospective multicenter observational study of the ALS-FTD spectrum"Andreas Hermann, Johannes Prudlo, Elisabeth Kasper, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 22, 2025
Self-assessment of amyotrophic lateral sclerosis functional rating scale on the patient's smartphone proves to be non-inferior to clinic data captureLaura Steinfurth, Torsten Grehl, Ute Weyen, et al.
European Journal of Neurology|March 10, 2023
Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis-a cross-sectional multicenter studyThomas Meyer, Erma Salkic, Torsten Grehl, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 11, 2025
Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis - assessment of treatment experience in a multicenter studySusanne Spittel, Torsten Grehl, Patrick Weydt, et al.
Nature Reviews. Neurology|May 20, 2024
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biologyMichael Benatar, Joanne Wuu, Edward D Huey, et al.
Pageof 18

Showing results (141-150 of 173) with videos related to

Sort By:
Pageof 18
Annals of Clinical and Translational Neurology|April 1, 2021
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatmentMaren Freigang, Claudia D Wurster, Tim Hagenacker, et al.
Neurobiology of Disease|August 10, 2018
Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi functionIsabel Paiva, Gaurav Jain, Diana F Lázaro, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 20, 2026
Minimum important slowing of disease progression as determined by the ALS functional rating scale - a survey of patient expectations toward disease-modifying drugs in ALSThomas Meyer, André Maier, Torsten Grehl, et al.
JAMA Neurology|January 10, 2022
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral SclerosisSimon Witzel, André Maier, Robert Steinbach, et al.
Nature Communications|January 11, 2022
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescentsNina Koerber, Alina Priller, Sarah Yazici, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 9, 2025
"The DESCRIBE-ALS-FTD study: a prospective multicenter observational study of the ALS-FTD spectrum"Andreas Hermann, Johannes Prudlo, Elisabeth Kasper, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 22, 2025
Self-assessment of amyotrophic lateral sclerosis functional rating scale on the patient's smartphone proves to be non-inferior to clinic data captureLaura Steinfurth, Torsten Grehl, Ute Weyen, et al.
European Journal of Neurology|March 10, 2023
Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis-a cross-sectional multicenter studyThomas Meyer, Erma Salkic, Torsten Grehl, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 11, 2025
Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis - assessment of treatment experience in a multicenter studySusanne Spittel, Torsten Grehl, Patrick Weydt, et al.
Nature Reviews. Neurology|May 20, 2024
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biologyMichael Benatar, Joanne Wuu, Edward D Huey, et al.
Pageof 18